对《中国药物性肝损伤诊治指南(2023年版)》两个问题的商榷

肝脏 ›› 2025, Vol. 30 ›› Issue (3): 286-291.

对《中国药物性肝损伤诊治指南(2023年版)》两个问题的商榷

于乐成, 刘鸿凌, 陈成伟

210002 江苏南京大学医学院附属金陵医院(东部战区总医院)感染病科与肝病中心(于乐成);100039 北京解放军总医院第五医学中心肝衰竭诊疗与研究中心(刘鸿凌);200052 上海海军军医大学第九O五医院感染肝病中心(陈成伟)

收稿日期:2025-02-08 出版日期:2025-03-31 发布日期:2025-06-16
通讯作者: 陈成伟,Email: ccw2@163.com

Received:2025-02-08 Online:2025-03-31 Published:2025-06-16

摘要/Abstract

摘要： 临床实践指南推荐意见的循证证据反映最佳临床证据现状, 根本意义是让患者得到最优的同质化治疗, 直接关系到医护人员的科学决策和患者健康。2023年再版的中国药物性肝损伤(DILI)诊治指南有两个重要问题值得商榷:(1)关于治疗药物推荐意见可能带来的问题;(2)所推荐的DILI严重程度分级标准缺失“急性肝衰竭(ALF)”这一独立层级,可能会对我国药物性肝功能衰竭和DILI临床诊治以及科研工作产生不利影响。

于乐成, 刘鸿凌, 陈成伟. 对《中国药物性肝损伤诊治指南(2023年版)》两个问题的商榷[J]. 肝脏, 2025, 30(3): 286-291.

/ 推荐

参考文献

[1] 张宁萍, 王吉耀, 陈世耀, 等. 我国消化内科临床实践指南或共识的评价[J]. 中华消化杂志, 2019, 39(9):613-618.
[2] 中华医学会杂志社指南与标准研究中心,世界卫生组织指南实施与知识转化合作中心. 2020中华医学会系列杂志发表指南评价报告[J]. 中华医学杂志,2021,101(24):1839-1847.
[3] 中国医药生物技术协会药物性肝损伤防治技术专业委员会,中华医学会肝病学分会药物性肝病学组.中国药物性肝损伤诊治指南(2023年版)[J].中华肝脏病杂志, 2023, 31(4): 355-384
[4] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 中华肝脏病杂志, 2015, 23(11): 810-820.
[5] Guyatt G H, Oxman A D, Vist G E, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008, 336(7650):924-926.
[6] Howick J, Chalmers I, Glasziou P, et al. Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence (Background Document). Oxford Centre for Evidence-Based Medicine. Accessible: May 31st 2024. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/explanation-of-the-2011-ocebm-levels-of-evidence.
[7] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组: 肝衰竭诊治指南(2012年版)[J]. 中华肝脏病杂志, 2013, 21(3):178-189.
[8] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1):38-44。
[9] Watkins P B, Seligman P J, Pears J S, et al. Using controlled clinical trials to learn more about acute drug-induced liver injury[J]. Hepatology, 2008, 48(5):1680-1689.
[10] Fontana R J, Watkins P B, Bonkovsky H L, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct[J]. Drug Saf, 2009, 32(1): 55-68.
[11] Borraz Y, Fernandez M C, Garcia-Muhoz B,et al. Would it be desirable to modify the cut-off point for definition of chronicity in drug-induced liver injury (DILI)? 61st Annual Meeting of the American Association for the Study of Liver Diseases: 2010, A270.
[12] Aithal G P, Watkins P B, Andrade R J, et al. Case definition and phenotype standardization in drug-induced liver injury[J]. Clin Pharmacol Ther, 2011, 89(6):806-815.
[13] 沈耕荣,余书文,董祥家,等.重症肝炎.天津: 天津科技出版社, 1990: 289-314.
[14] 段钟平, 陈煜. 肝衰竭总论//贾继东, 任红. 王宝恩肝脏病学. 北京: 科学出版社,2022:507-515.
[15] Reuben A, Koch D G, Lee W M, et al. Drug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study. Hepatology, 2010, 52(6):2065-2076.
[16] Sarin S K, Choudhury A, Sharma M K, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update[J]. Hepatol Int, 2019, 13(4):353-390.
[17] Stravitz R T, Fontana R J, Karvellas C, et al. Future directions in acute liver failure[J]. Hepatology, 2023, 78:1266-1289.
[18] Drug-induced liver injury (DILI): Current status and future directions for drug development and the post-market setting. A consensus by a CIOMS Working Group. Geneva 2020. ISBN: 978-929036099-5. Accessible: 15th June, 2024. https://cioms.ch/publications/product/drug-induced-liver-injury/.